Dr Jameel Feshitan earned his Bachelor of Science in chemical engineering at University of Missouri,
Columbia in 2007, with a minor in mathematics, and attained a PhD in chemical engineering at Columbia
University in New York City in 2012. He has 15 years’ experience performing research on ultrasound
contrast agents known as microbubbles for diagnostic imaging, ultrasound targeted drug/gene delivery and
oxygen delivery to treat hypoxia and acute respiratory distress syndrome. He helped pioneer a novel
method to make the holy grail in microbubble engineering – stable monodisperse microbubbles which are
optimized for precise, non-invasive and efficient anti-cancer drug/gene delivery in combination with
medical ultrasound. In 2020, he founded the biotech startup, Advanced Microbubbles Inc, with the goal of
clinical translation of the ultrasound triggered monodisperse microbubbles as the state-of-the-art
drug/gene delivery platform to overcome the current challenges facing conventional drug delivery such as
poor drug penetration to the disease region, terrible drug side-effects and poor survival outcomes. His
startup’s platform will focus on treatment of various solid tumor cancers including pancreatic, liver, breast,
colorectal cancer and neurological disorders such as Alzheimer’s disease, Parkinson’s disease, ALS etc.
Did you know?
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
The question for Sumit Sinha and Mukesh Bansal in February 2019 was which would come first: The funding for their seed round or the sale of their Hyundai hatchbacks.
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
Tesh Mbaabu rarely showed up to his freshman computer science class at the University of Nairobi. His classmate Mesongo Sibuti noticed.
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.